Anti-cancer activity and cellular uptake of 7,3′,4′- and 7,8,4′-trihydroxyisoflavone in HepG2 cells under hypoxic conditions

References

• Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21(9):541–557.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–693.
   PubMed Web of Science ®Google Scholar
• Chang Y, Jeong SW, Young Jang J, Kim JY. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(21):1–20.
   Web of Science ®Google Scholar
• Lin Z-H, Jiang J-R, Ma X-K, Chen J, Li H-P, Li X, Wu X-Y, Huang M-S, Lin Q. Prognostic value of serum HIF-1alpha change following transarterial chemoembolization in hepatocellular carcinoma. Clin Exp Med. 2021;21(1):109–120.
   PubMed Web of Science ®Google Scholar
• Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1alpha and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8(4):297–302.
   PubMedGoogle Scholar
• Korbecki J, Siminska D, Gassowska-Dobrowolska M, Listos J, Gutowska I, Chlubek D, et al. Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-kappaB activation: a review of the molecular mechanisms. Int J Mol Sci. 2021;22(19):10701.
   PubMed Web of Science ®Google Scholar
• Huang M, Wang LONG, Chen J, Bai M, Zhou C, Liu S, Lin QU. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1alpha is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int J Oncol. 2016;48(5):2144–2154.
   PubMed Web of Science ®Google Scholar
• Yu S, Zhou R, Yang T, Liu S, Cui Z, Qiao Q, Zhang J. Hypoxia promotes colorectal cancer cell migration and invasion in a SIRT1-dependent manner. Cancer Cell Int. 2019;19(1):116.
   PubMedGoogle Scholar
• Wu S, Lu H, Bai Y. Nrf2 in cancers: A double-edged sword. Cancer Med. 2019;8(5):2252–2267.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501.
   PubMed Web of Science ®Google Scholar
• Li Y, Gao ZH, Qu XJ. The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2015;116(3):216–221.
   PubMed Web of Science ®Google Scholar
• Liao C-Y, Lee C-C, Tsai C-c, Hsueh C-W, Wang C-C, Chen I-H, Tsai M-K, Liu M-Y, Hsieh A-T, Su K-J, et al. Novel investigations of flavonoids as chemopreventive agents for hepatocellular carcinoma. Biomed Res Int. 2015;2015:840526–840542.
   Web of Science ®Google Scholar
• Roh C. Microbial transformation of bioactive compounds and production of ortho-dihydroxyisoflavones and glycitein from natural fermented soybean paste. Biomolecules. 2014;4(4):1093–1101.
   PubMedGoogle Scholar
• Huang PH, Tseng CH, Lin CY, Lee CW, Yen FL. Preparation, characterizations and anti-pollutant activity of 7,3',4'-trihydroxyisoflavone nanoparticles in particulate matter-induced HaCaT keratinocytes. Int J Nanomedicine. 2018;13:3279–3293.
   PubMed Web of Science ®Google Scholar
• Kim E, Kang YG, Kim JH, Kim YJ, Lee TR, Lee J, et al. The antioxidant and anti-inflammatory activities of 8-hydroxydaidzein (8-HD) in activated macrophage-like RAW264.7 cells. Int J Mol Sci. 2018;19(7):1828.
   PubMed Web of Science ®Google Scholar
• Wu G, Robertson DH, Brooks CL, 3rd, Vieth M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem. 2003;24(13):1549–1562.
   PubMed Web of Science ®Google Scholar
• Tzeng WS, Teng WL, Huang PH, Lin TC, Yen FL, Shiue YL. Pterostilbene nanoparticles downregulate hypoxia-inducible factors in hepatoma cells under hypoxic conditions. Int J Nanomed. 2021;16:867–879.
   PubMed Web of Science ®Google Scholar
• Castillo Bennett J, Silva P, Martinez S, Torres VA, Quest AFG. Hypoxia-induced caveolin-1 expression promotes migration and invasion of tumor cells. Curr Mol Med. 2018;18(4):199–206.
   PubMed Web of Science ®Google Scholar
• Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The role of sirtuins in antioxidant and redox signaling. Antioxid Redox Signal. 2018;28(8):643–661.
   PubMed Web of Science ®Google Scholar
• Dash R, Uddin MM, Hosen SMZ, Rahim ZB, Dinar A, Kabir M, Sultan RA, Islam A, Hossain MK. Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer. Bioinformation. 2015;11(12):543–549.
   PubMedGoogle Scholar
• Chen L, Lin G, Chen K, Liang R, Wan F, Zhang C, Tian G, Zhu X. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma. J Cancer. 2020;11(24):7291–7301.
   PubMed Web of Science ®Google Scholar
• Rajesh G, Harshala S, Dhananjay G, Jadhav A, Vikram G. Effect of hydroxyl substitution of flavone on angiogenesis and free radical scavenging activities: a structure-activity relationship studies using computational tools. Eur J Pharm Sci. 2010;39(1-3):37–44.
   PubMed Web of Science ®Google Scholar
• Gandhi J, Khera L, Gaur N, Paul C, Kaul R. Role of modulator of inflammation cyclooxygenase-2 in gammaherpesvirus mediated tumorigenesis. Front Microbiol. 2017;8:538.
   PubMed Web of Science ®Google Scholar
• Toomey DP, Murphy JF, Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon. 2009;7(3):174–180.
   PubMed Web of Science ®Google Scholar
• Liu W-R, Jin L, Tian M-X, Jiang X-F, Yang L-X, Ding Z-B, Shen Y-H, Peng Y-F, Gao D-M, Zhou J, et al. Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016;40(2):169–178.
   PubMed Web of Science ®Google Scholar
• Mao X, Wong SYS, Tse EYT, Ko FCF, Tey SK, Yeung YS, Man K, Lo RC-L, Ng IO-L, Yam JWP, et al. Mechanisms through which hypoxia-induced caveolin-1 drives tumorigenesis and metastasis in hepatocellular carcinoma. Cancer Res. 2016;76(24):7242–7253.
   PubMed Web of Science ®Google Scholar
• Tam SY, Wu VWC, Law HKW. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1alpha and beyond. Front Oncol. 2020;10:486.
   PubMed Web of Science ®Google Scholar
• Toth RK, Warfel NA. Strange bedfellows: nuclear factor, erythroid 2-like 2 (Nrf2) and hypoxia-inducible factor 1 (HIF-1) in tumor hypoxia. Antioxidants (Basel). 2017;6(2):27.
   PubMedGoogle Scholar
• Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):585–597.
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873–9886.
   PubMed Web of Science ®Google Scholar
• Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234(5):5683–5699.
   PubMed Web of Science ®Google Scholar
• Zhang G, He J, Ye X, Zhu J, Hu X, Shen M, Ma Y, Mao Z, Song H, Chen F, et al. beta-Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS-mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma. Cell Death Dis. 2019;10(4):255.
   PubMedGoogle Scholar
• Ho YJ, Thao DT, Yeh CK. Overcoming hypoxia-induced drug resistance via promotion of drug uptake and reoxygenation by acousto-mechanical oxygen delivery. Pharmaceutics. 2022;14(5):902.
   PubMed Web of Science ®Google Scholar